Wharton's Jelly derived mesenchymal stem cell therapy(Ankara Universitesi Teknokent)

N/A

Report date: 2023/04/11 20:00:23

Base Information

Drug NameWharton's Jelly derived mesenchymal stem cell therapy(Ankara Universitesi Teknokent)
Drug Alias NameWJ-MSC
ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseRetinal DystrophiesRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTurkey
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnkara Universitesi Teknokent
China Registration ClassN/A

Develop Information

Active CompaniesAnkara Universitesi TeknokentInstituto Distrital de Ciencia, Biotecnología e Innovación en Salud
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseRetinitis Pigmentosa
Inactive IndicationsRetinal Dystrophies

Other Information

ATC CodeN/A
Related LinksN/A